Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Obesity
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Glomerulonephritis
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB - ACTION3 - Dimerix Bioscience Pty LtdSee more
